Gastroenterologyclinical trialEtrasimod
Etrasimod Shows Robust Induction and Maintenance Efficacy in East Asian Patients with Moderate–Severe Ulcerative Colitis
By MedXY|Nov 9, 2025
A phase 3 randomized trial in East Asia found oral etrasimod 2 mg superior to placebo for induction and maintenance of clinical remission in moderate–severe ulcerative colitis, with manageable safety and notable ALT elevations.
